The IKK complex may be a good target to specifically interfere with NF-κB activation in TRAIL-resistant cancer cells, such that gene therapy strategies involving exogenous TRAIL expression with concurrent inhibition of the NF-κB pathway through IKK modulation of function may extend the therapeutic index of TRAIL for patients with lung cancer. This evidence concerns the gene TNFSF10 and lung carcinoma.